In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dr. Falk Pharma GmbH

www.drfalkpharma.de

Latest From Dr. Falk Pharma GmbH

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Financing StartUps and SMEs

Pipeline Watch: Phase III Progress With Biosimilar Adalimumab And Trastuzumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials

Nestlé Gets Serious With Seres Deal

The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.

BioPharmaceutical Deals

Lipid Therapeutics Plans U.S. Ulcerative Colitis Trials With Lipid Therapy

U.S. Phase III studies could start in the next 12 months with Lipid Therapeutics’ purified formulation of phosphatidylcholine to reverse deficiencies in the gastrointestinal mucosal barrier in patients with ulcerative colitis.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Hepatic (Liver)
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Dr. Falk Pharma GmbH
  • Senior Management
  • Roland Greinwald, PhD, Managing Dir.
  • Contact Info
  • Dr. Falk Pharma GmbH
    Phone: (49) 761 15 14 0
    Leinenweberstrasse 5
    P.O. Box 6529 Freiburg, D-79108
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register